Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

NCT03043313 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Adenocarcinoma

Interventions

DRUG: Trastuzumab
DRUG: Tucatinib

Sponsor

Seagen Inc.

Collaborators

[object Object]
[object Object]